Youngevity (NASDAQ:YGYI) Reshapes Board To Be Majority Independent Directors.

Youngevity International, Inc. (Nasdaq: YGYI) today announced that effective February 11, 2020, in order to maintain compliance with the corporate governance requirements of The Nasdaq Capital Market, and specifically Listing Rule 5605(b) which provides that a listed company’s board of directors shall be comprised of a majority of independent directors, Michelle Wallach and Richard Renton, two non-independent members of the Board of Directors of Youngevity International, Inc. (the “Company”), resigned as members of the Board of Directors of the Company.  Steve Wallach, CEO of Youngevity International will continue as a board member and will remain the Chairman of the Board and Dave Briskie, President and CFO of Youngevity will also remain on the Board of Directors.

Khrysos Industries, Inc. a wholly owned subsidiary of Youngevity International, Inc. (NASDAQ: YGYI) secures $1.2 Million of Tolling Revenue for February Shipping Representing 42% of Monthly Tolling Capacity

Khrysos Industries, Inc. a wholly owned subsidiary of Youngevity International, Inc.​ (NASDAQ: YGYI), announced today that its tolling operation operating within its 82,000 square foot facility in Orlando, Florida has filled 42% of its available capacity generating $1.2 million of revenue for February tolling production. Khrysos Industries tolling operation represents one revenue segment of YGYI’s hemp enterprise. The company began bringing online the state-of-the-art facility that features a 46,200 sq. ft. production area that includes 5,200 sq. ft. of class C7 sterile capable workspace and is powered via a redundant utility system for continuous operation. Khrysos also plans to bring online its finished goods production in February.

Youngevity Rings in Wellness Week 2020 at Nasdaq Closing Bell

Youngevity® International, Inc. (NASDAQ: YGYI) was recognized by Nasdaq as a 2020 “Wellness Week” company and selected to ring the closing bell on January 7, 2020 at the Nasdaq MarketSite in Times Square. On January 7, 2020, Youngevity’s executive leadership team gathered alongside YGYI Ambassadors Marilu Henner and Dr. James Rouse, company distributors and winners of Youngevity’s 2019 Better Health Challenge.

Youngevity Selected as Fit Week Company 2020, YGYI to Ring Nasdaq Closing Bell on January 7

Youngevity® International, Inc. (NASDAQ: YGYI) today announced it will ring in the new year on January 7, 2020 at The Nasdaq Stock Market Closing Bell ceremony in Times Square. In celebration of Nasdaq’s ninth annual “Fit Week,” Youngevity’s executive leadership will gather alongside esteemed company distributors, as well as members of the Youngevity team and Celebrity Brand Ambassadors Marilu Henner and Dr. James Rouse to ring the closing bell.

Youngevity International, Inc. Announces Closing of $5.58 Million Public Offering of Series D Cumulative Redeemable Perpetual Preferred Stock

YGYI today announced the closing of its previously announced underwritten public offering of 245,398 shares of its 9.75% Series D Cumulative Redeemable Perpetual Preferred Stock at a price to the public of $22.75 per share. The Company received gross proceeds of approximately $5.58 million from the offering. The shares of Series D Preferred Stock trade on the Nasdaq Capital Market under the symbol “YGYIP.”  The shares of Series D Preferred Stock are not convertible into or exchangeable for any of the company’s other securities.

Youngevity International, Inc. Announces Timing of Regular Monthly Dividend for December 2019 for Series “D” Cumulative Redeemable Perpetual Preferred Stock

Youngevity International, Inc. (NASDAQ: YGYI), a leading multi-channel lifestyle company, today announced the timing for the payment of its declared regular monthly dividend of $0.203125 per share of its 9.75% Series D Cumulative Redeemable Perpetual Preferred Stock (NASDAQ:YGYIP) for December 2019. The dividend will be payable on January 15, 2020 to holders of record as of December 31, 2019. The dividend will be paid in cash.